Press Release



DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.

CONTACT INVESTOR RELATIONS MEDIA RELATIONS

SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135)

CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121)

Dr. Reddy's subsidiary OctoPlus is now 'Dr. Reddy's Research and Development B.V.'

For Immediate Release

Leiden, the Netherlands, January 19, 2017 - Dr. Reddy's Laboratories Ltd today announced the renaming of its 'Dutch research centre Octoplus and affiliated legal entities of OctoPlus' to 'Dr. Reddy's Research and Development B.V.' with immediate effect.

OctoPlus, a leading company for the development of long-acting injectables and liposomal pharmaceutical formulations, was acquired by Dr. Reddy's in 2013 and became a fully integrated Centre of Excellence for the development of Dr. Reddy's complex injectables.

"The renaming of our legal entity reflects our transformation from an external service provider into a seamlessly integrated R&D centre for Dr. Reddy's." said Roger Friedrichs, General Manager and Site Head, Dr. Reddy's Research and Development B.V. "Today we are focusing all our efforts on internal projects, working closely with the global development and manufacturing sites of Dr. Reddy's."

Located in the Bio Science Park Leiden, Dr. Reddy's Research and Development B.V. is one of the two R&D centres based in Europe. The centre has over 100 employees from more than 20 countries.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.